Immunoglobulin Levels in the Cerebrospinal Fluid

D. RIDDOCH,* M.B., M.R.C.P. ; R. A. THOMPSON,† M.B., B.SC., M.R.C.P.

British Medical Journal, 1970, 1, 396-399

Summary: The immunoglobulins G, A, M, and D have been measured in the cerebrospinal fluid of 207 patients with neurological disease. Raised levels of IgG, expressed as a percentage of total cerebrospinal fluid (C.S.F.) protein, were found in 62% of 45 cases of multiple sclerosis compared with 14% of 160 cases with various other neurological disorders. Thus measurement of the IgG level is probably a useful confirmatory investigation in multiple sclerosis. IgA and IgM were found only in the C.S.F. of patients with a raised protein level, and IgD was not detected.

Introduction

Examination of the cerebrospinal fluid obtained by lumbar puncture has been a valuable aid to neurological diagnosis since its introduction over 70 years ago. More recently, electrophoretic methods have added to our knowledge of the individual protein fractions in health and disease; their disadvantage lies in the need for large quantities of fluid which require preliminary concentration, with possible resulting loss of protein and alteration in its physicochemical properties. Immunochemical methods are specific for a single protein and can be made sensitive enough to allow use of small amounts of unconcentrated cerebrospinal fluid (C.S.F.). The single radial diffusion method has been used to study the four main human immunoglobulins—IgG, IgA, IgM, and IgD—in the C.S.F. of patients with neurological disorders.

Methods

C.S.F. specimens were obtained from 207 unselected patients with a variety of definite or suspected neurological disorders—204 were lumbar fluids, 2 were ventricular, and 1 was cisternal. They were examined without concentration after the exclusion of macroscopically blood-stained specimens.

The immunoglobulin content was estimated by the single radial diffusion method of Fahey and McKelvey (1965), using specific antisera to human IgG, IgA, IgM, and IgD, prepared in sheep, according to the method described by Rowe *et al.* (1968). The standard for the IgG was a preparation of ether fractionated human IgG (Kekwick and Mackay, 1954), obtained from the Lister Institute, Herts., England. The standard for IgA and IgM was the serum of a healthy individual containing a known concentration of these immunoglobulins. The standard for IgD was the serum of another healthy individual with a high level of this protein. The lower limit of the sensitivity of the method was 1 mg./100 ml. for IgG and IgD, 3 mg./100 ml. for IgA, and 1.5 mg./100 ml. for IgM.

The total protein in the C.S.F. was estimated by the method

* Senior Registrar in Neurology, Queen Elizabeth Hospital, Birmingham 15.
† Lecturer in Experimental Pathology, the University, Birmingham 15.

of Folin (Lowry *et al.*, 1951), on an AutoAnalyzer (Technicon Ltd.), with a known concentration of bovine serum albumin (Armour Laboratories Ltd.) as standard. The levels varied between 16 and 800 mg./100 ml. In four cases where the protein level was very high insufficient C.S.F. was available for this method of estimation. Accordingly, in these cases only, the results obtained independently in the hospital biochemistry laboratory by the sulphosalicylic turbidimetric technique were accepted.

Immunoelectrophoresis of concentrated C.S.F. was carried out against antihuman IgG by the method of Grabar and Williams (1953) in 1.5% Noble agar (Difco) on the first 50 cases studied.

Results

IgD was never detected in the C.S.F. even in those with moderate serum levels of this immunoglobulin.

IgM was found in only four patients, all of whom had a total C.S.F. protein exceeding 150 mg./100 ml.; the highest concentration was 7 mg./100 ml. in a patient with a total protein of 800 mg./100 ml. Nevertheless, the C.S.F. of five other cases (including one of IgG myeloma) with protein values in excess of 150 mg./100 ml. did not contain detectable IgM. It was concluded from the clinical protocol of these nine cases that the presence or absence of IgM had no diagnostic significance.

IgG Expressed as a Percentage of the Total C.S.F. Protein in 207 Cases According to Diagnosis

No. of Cases	Diagnosis	IgG as % of Total Protein	
		Mean	Range
45	Multiple sclerosis	18.9	2.8-52.9
14	Epilepsy	7.4	4.0-16.1
14	Cervical spondylotic myelopathy	7.5	5.2-10.9
10	Presenile dementia	11.4	2.6-47.7
9	Peripheral neuropathy	10.6	5.1-16.2
9	Cerebral arteriosclerosis	6.8	3.6-13.3
8	Cerebral and spinal tumour	11.3	5.5-20.8
6	Motor neurone disease	9.0	4.3-12.5
3	Spinocerebellar degeneration	5.4	3.0-6.7
3	Neurosyphilis	13.1	9.3-15.3
5	Retrolubar neuritis	12.2	5.0-34.0
5	Inflammatory disease	10.3	7.1-14.6
4	Metabolic disturbance	6.1	2.3-9.6
4	Endocrine disorder	8.4	6.7-11.6
7	Chronic degenerative disease	10.3	7.1-14.6
9	Lumbar disc prolapse	8.6	3.4-11.9
2	Multiple myeloma	64.1	51.6-76.7
6	Psychiatric disorder	8.1	3.1-10.0
29	Miscellaneous	8.1	2.6-17.8
15	Uncertain	10.7	4.0-23.6

IgA was found in 33 cases (16%). This immunoglobulin was found only in C.S.F. specimens where the total protein was 40 mg./100 ml. or above. IgA was present in concentrations up to 42 mg./100 ml. and constituted 1.5-14% of the total protein. High protein values increased the likelihood of IgA being detected (Fig. 1). It was found in seven out of nine cases of

peripheral neuropathy in which the total protein ranged from 44 to 800 mg./100 ml. It was detected in only 5 out of 45 cases of multiple sclerosis. Its presence or absence had no additional diagnostic value.

IgG was found in all the 207 specimens of cerebrospinal fluid examined (see Table). Its concentration varied considerably but, as can be seen in Fig. 2, 80% of cases had a level of less than 8 mg./100 ml. Two instances of high values (48 and 230 mg./100 ml.) were found in patients with IgG myeloma,

that a large number of the 45 clinically definite cases of multiple sclerosis had a raised IgG content. Raised levels were found in 28 (62%) as opposed to 23 (14%) of 160 cases with various other neurological diseases (Fig. 5). The mean percentage level of IgG in multiple sclerosis was 18.9 (S.D. 10.7) as opposed to 9.0 (S.D. 5.2) for the remainder. Further analysis of the multiple sclerosis cases showed no correlation between the IgG level and the age or sex of patient, length of history, or severity of disease. Cases were divided into active (clear-cut

FIG. 1.—Percentage of cases containing IgA in the C.S.F., in relation to total protein. Shaded area indicates IgA present.

FIG. 2.—C.S.F. IgG levels in all 207 cases.

FIG. 3.—C.S.F. IgG levels in 205 cases (multiple myeloma), expressed as a percentage of the total C.S.F. protein.

and these were rejected from further study. In the remaining 205 cases it was clear that the absolute level of IgG present in the C.S.F. was related to the total protein, and so the results were expressed as a percentage of the protein estimated by the Folin method (Fig. 3). Subsequently in this paper the IgG level will continue to be expressed in this way. As the series did not contain any normal controls we have taken as our upper limit of normal the figure of 13% obtained by Yahr *et al.* (1954), who used an immunochemical method.

Within this somewhat arbitrary level it can be seen (Fig. 4)

FIG. 4.—Percentage C.S.F. IgG levels in 45 cases of multiple sclerosis. Arrow indicates upper limit of normal.

FIG. 5.—Percentage C.S.F. IgG levels in 160 cases with miscellaneous neurological disorders.

relapse within the previous three months) and quiescent, without there being any significant difference in IgG level between the groups. Some correlation was, however, established between the C.S.F. IgG level and the presence of an abnormal Lange test. Colloidal gold curves were carried out in 38 of the 45 cases of multiple sclerosis. Eight showed first zone changes, and all of these had raised IgG levels, with a mean of 27.3% (S.D. 6.2). In contrast the remaining 30 cases with negative Lange curves had a mean of 16.5% (S.D. 9.2), and 16 of these exceeded the normal IgG level. The difference is significant (difference of means = 3.9 times the standard error). As only three cases of multiple sclerosis were found to have a pleocytosis in the C.S.F. it was not possible to analyse this aspect in relation to IgG content.

Of the 45 cases only one had a total protein greater than 100 mg./100 ml., 29 cases had less than 50 mg./100 ml., and 15 were in the range 50–100 mg./100 ml. The mean percentage IgG level in each of these two groups was very similar (18.8 and 19.2 respectively). Thus it appeared that in the multiple sclerosis cases a raised C.S.F. protein had little or no effect on the percentage IgG level.

The electrophoretic mobility of gammaglobulin in the C.S.F. of multiple sclerosis cases has been studied by various authors. While some (Kutt *et al.*, 1960; Dencker and Swahn, 1961; Clausen *et al.*, 1964) found the main increase in the slowly migrating cathodic fraction, others (Lowenthal *et al.*, 1960; Lamoureux and Borduas, 1966) noted denser anodic precipitation. In view of these conflicting findings, the first 50 C.S.F. specimens were concentrated 5 to 10 times by ultrafiltration and subjected to immunoelectrophoresis in agar against antihuman IgG. Among these were several cases of multiple sclerosis in which the IgG was always observed to migrate to a position compatible with normal serum IgG. One specimen from a patient not suffering from multiple sclerosis showed a doubtfully increased mobility of the IgG towards the anode.

Analysis of the 160 cases with miscellaneous neurological diagnoses was also carried out. It can be seen (Fig. 6) that raised percentage levels of IgG are more common in C.S.F.s with a high total protein content, and are present in 7 out of 12 cases where this exceeds 100 mg./100 ml. The 23 cases

with a raised percentage of IgG included three with suspected but not clinically definite multiple sclerosis. In most of the non-multiple sclerosis cases with a raised IgG level the rise was small. Only four of the miscellaneous 160 cases had figures above 20% as opposed to 19 of the 45 cases of multiple

FIG. 6.—Percentage of non-multiple sclerosis cases showing a raised C.S.F. IgG level in relation to total protein. Shaded area indicates IgG > 13%.

sclerosis. The diagnoses in these four cases were presenile dementia, bilateral retrobulbar neuritis (? demyelinating), cerebral metastases, and an undiagnosed neurological condition in a woman showing a raised serum IgG level. IgG levels in the non-multiple sclerosis group showed no correlation with age. A curious feature, however, emerged in that the values for 94 males (mean 10.1, S.D. 5.9) were significantly higher than those for 66 females (mean 7.6, S.D. 3.7) (difference of means = 3.3 times the standard error). The reason for this is uncertain, as high total protein values did not predominate in the C.S.F. specimens from male cases.

Certain diagnostic groups were considered in greater detail. Cervical spondylosis (14 cases), motor neurone disease (6 cases), and spinocerebellar degeneration (3 cases), all of which may be confused clinically with multiple sclerosis, showed normal levels. Of nine cases of cerebral arteriosclerosis, a slightly raised IgG content (13.3%) was found in only one. Of the three cases of neurosyphilis in this series, figures of 9.3 and 14.8% were present in two cases of burnt-out tabes and 15.3% in the ventricular fluid of a man with active meningo-vascular syphilis. Normal levels were found in two childhood cases of transverse myelitis, and in four out of five cases of retrobulbar neuritis. The fifth case, with a figure of 34%, was a man of 26 in whom the diagnosis lay between demyelination of the optic nerves and Leber's disease. Out of nine cases of peripheral neuropathy IgG levels were raised in three, all of which had total C.S.F. proteins exceeding 200 mg./100 ml. Two out of 10 cases of presenile dementia had raised levels (one very high at 47.7%), and both of these had shown a rapidly progressive mental deterioration with extrapyramidal signs. By contrast, three patients with a biopsy-proved Alzheimer's disease all had IgG levels under 4%.

Discussion

Interest in the protein fractions of C.S.F. was stimulated by the work of Kabat *et al.* (1942), who first applied Tiselius electrophoresis to this fluid, and found increased gammaglobulin levels in neurosyphilis, which were independent of serum changes. Similar abnormality was apparent in two cases of multiple sclerosis. Their findings have largely been confirmed by many authors who have used paper and gel electrophoresis (Cumings, 1953; Plum and Fog, 1959; Bronsky *et al.*, 1960; Ivers *et al.*, 1961; Schapira and Park, 1961; Johns-

clottir and Lowenthal, 1962; Bergmann *et al.*, 1964; Bradshaw, 1964; Clausen *et al.*, 1964; Cosgrove and Agius, 1966), immunoelectrophoresis (Dechaume *et al.*, 1962; Laterre *et al.*, 1962; Dencker, 1964; Lamoureux and Borduas, 1966), chemical precipitation (Roboz *et al.*, 1953; Volk *et al.*, 1955; Ziegler and Ross, 1955; Hanok, 1961; Foster and Horn, 1962; Prineas *et al.*, 1966), immunoprecipitation (Kabat *et al.*, 1948), and electroimmunodiffusion (Schneck and Claman, 1969). The proportion of multiple sclerosis cases showing a raised gammaglobulin has varied between the 40% of Bradshaw (1964) and the 88% of Schapira and Park (1961). Two large series of patients with multiple sclerosis analysed by Tourtellotte (1963) and by Yahr *et al.* (1954) showed raised levels in 50% of 387 cases and 66.5% of 244 cases respectively. The latter authors also found abnormal gammaglobulin levels in 74% of 35 cases of neurosyphilis.

The reason why only a proportion of multiple sclerosis cases show a raised gammaglobulin level in the C.S.F. remains obscure. Several workers have tried to correlate this feature with various aspects of the disease, including duration, severity, mode of onset, activity, number of relapses, site of lesion, and the C.S.F. cell count or its total protein (Kabat *et al.*, 1950; Roboz *et al.*, 1953; Yahr *et al.*, 1954; Bronsky *et al.*, 1960; Hanok, 1961; Ivers *et al.*, 1961; Schapira and Park, 1961; Bergmann *et al.*, 1964; Cosgrove and Agius, 1966; Lamoureux and Borduas, 1966; Prineas *et al.*, 1966). The findings have varied from one group to another, with no clear picture emerging, and, as already mentioned, we have failed to find a correlation between clinical aspects of the disease and percentage IgG level. Nevertheless, most authors have found, as we have, a good correlation between gammaglobulin levels and paretic changes in the Lange curve. This is not surprising, as it is well established that gammaglobulin causes precipitation of colloidal gold, which can be inhibited by albumin (Gray, 1942; Kabat *et al.*, 1942; Freedman and Merritt, 1950; Press, 1956). Several of our multiple sclerosis cases, however, had a negative Lange curve in the presence of a raised C.S.F. IgG. The site of production of the pathological globulin remains uncertain (Bing and Neel, 1942; Tourtellotte and Parker, 1966; Cohen and Bannister, 1967). The consensus of opinion (Field, 1954; Caspary, 1965; Lippincott *et al.*, 1965) is that the abnormal globulin is formed locally, either in the neuraxis itself or from the white cells in the C.S.F., rather than diffusing from the plasma through a selectively permeable blood-brain barrier.

After excluding neurosyphilis and multiple sclerosis most authors have found a small percentage of cases with other neurological diseases which showed a raised gammaglobulin level, and we obtained a figure of 13% (21 out of 157), which falls to 10% when cases with a total protein of 100 mg./100 ml. or less are considered. Raised levels have particularly been noted by other workers in subacute sclerosing panencephalitis (Dencker and Kolár, 1965) and also in postexanthematous and postvaccinal "allergic" encephalomyelitis. In the present series higher than usual levels of IgG were found in a variety of disorders. Nevertheless, those cases likely to be confused clinically with multiple sclerosis showed uniformly normal levels. The results in presenile dementia are interesting and may suggest a method of separating the different groups.

Our findings of IgA and IgM in cerebrospinal fluids with a raised total protein are in agreement with the work of Laterre *et al.* (1962) and Schneck and Claman (1969), who also found their presence to be of no diagnostic value. In normal people the globulins of higher molecular weight are absent from the C.S.F., or are present in only minute quantities (Dencker *et al.*, 1961; Burtin, 1964; Matzke and Clausen, 1965; Ursing, 1965).

Though IgD was not detected in this series by the method used, Tavolato and De Zanche (1968), using immunoelectro-

phoresis of concentrated C.S.F., found it in 19 out of 30 neurological cases. It was absent or scarcely apparent in 10 controls. Its presence was related to the total protein level.

That abnormalities of the serum protein fractions are reflected in the C.S.F. is well recognized. Our two cases of IgG myeloma had very high levels of this immunoglobulin in the cerebrospinal fluid: 76.7% (spinal block) and 51.6%. In the former case immunoelectrophoresis showed that the myeloma protein was clearly the dominant protein present. Though Volk *et al.* (1955) recognized specific serum protein changes in multiple sclerosis, most authors have found no significant abnormality (Schapira and Park, 1961; Bradshaw, 1964). In the present series qualitative immunoglobulin estimations were carried out on the sera of 11 multiple sclerosis and 42 non-multiple sclerosis cases. Apart from the two examples of IgG myeloma, this immunoglobulin was raised in the serum of only one patient. All the multiple sclerosis cases showed normal levels.

Conclusion

The main interest of our findings has been in the immunoglobulin G fraction and its value in the diagnosis of multiple sclerosis. Though a small proportion of other neurological disorders show a raised IgG in the C.S.F., the rise tends to be small, and is more common when the total protein exceeds 100 mg./100 ml. In multiple sclerosis this total protein value is reached in only some 3% of patients (Locoge and Cumings, 1958). Thus the finding of a high percentage of IgG in the C.S.F. in the presence of a normal or moderately raised total protein must immediately suggest the diagnosis of multiple sclerosis in clinically doubtful cases.

We wish to express our gratitude to Professor J. Hardwicke, in whose department the total C.S.F. protein estimations were carried out by Miss V. Bayliss. Our thanks are also due to Dr. J. M. Jefferson and Dr. Michael Small, who gave valuable help and advice, in addition to providing most of the patients studied. Dr. J. A. H. Waterhouse kindly advised us on the statistical interpretation of the results.

REFERENCES

- Bergmann, L., Gilland, O., Olanders, S., and Svennerholm, L. (1964). *Acta Neurologica Scandinavica*, **40**, Suppl. No. 10, p. 33.
- Bing, J., and Neel, A. V. (1942). *Acta Medica Scandinavica*, **111**, 57.
- Bradshaw, P. (1964). *Journal of the Neurological Sciences*, **1**, 374.
- Bronsky, D., Kaplitz, S. E., Muci, J., Dubin, A., and Chesrow, E. J. (1960). *Journal of Laboratory and Clinical Medicine*, **56**, 382.
- Burtin, P. (1964). In *Immuno-Electrophoretic Analysis*, edited by P. Grabar and P. Burtin, p. 244. Amsterdam, Elsevier.
- Caspari, E. A. (1965). *Journal of Neurology, Neurosurgery and Psychiatry*, **28**, 61.
- Clausen, J., Matzke, J., and Gerhardt, W. (1964). *Acta Neurologica Scandinavica*, **40**, Suppl. No. 10, p. 49.
- Cohen, S., and Bannister, R. (1967). *Lancet*, **1**, 366.
- Cosgrove, J. B. R., and Agius, P. (1966). *Neurology (Minneapolis)*, **16**, 197.
- Cumings, J. N. (1953). *Journal of Neurology, Neurosurgery and Psychiatry*, **16**, 152.
- Dechaume, J., Manuel, Y., Bourrat, C., Creysse, R., and Robert, J. (1962). *Journal de Médecine de Lyon*, **43**, 589.
- Dencker, S. J. (1964). *Acta Neurologica Scandinavica*, **40**, Suppl. No. 10, p. 57.
- Dencker, S. J., Brønneham, R., and Swahn, B. (1961). *Neurology (Minneapolis)*, **11**, 441.
- Dencker, S. J., and Kolář, O. (1965). *Acta Neurologica Scandinavica*, **41**, Suppl. No. 13, p. 135.
- Dencker, S. J., and Swahn, B. (1961). *Lunds Universitets Arsskrift*, **57**, Suppl. No. 10.
- Fahev, J. L., and McKelvey, E. M. (1965). *Journal of Immunology*, **94**, 84.
- Field, E. O. (1954). *Journal of Neurology, Neurosurgery and Psychiatry*, **17**, 228.
- Foster, J. B., and Horn, D. B. (1962). *British Medical Journal*, **1**, 1527.
- Freedman, D. A., and Merritt, H. H. (1950). *Research Publications of the Association for Research into Nervous and Mental Diseases*, **28**, 428.
- Grabar, P., and Williams, C. A. (1953). *Biochimica et Biophysica Acta*, **10**, 193.
- Gray, S. J. (1942). *Proceedings of the Society for Experimental Biology and Medicine*, **51**, 401.
- Hanok, A. (1961). *Journal of Laboratory and Clinical Medicine*, **57**, 42.
- Ivers, R. R., McKenzie, B. F., McGuckin, W. F., and Goldstein, N. P. (1961). *Journal of the American Medical Association*, **176**, 515.
- Johnsclottir, K., and Lowenthal, A. (1962). *World Neurology*, **3**, 659.
- Kabat, E. A., Freedman, D. A., Murray, J. P., and Knaub, V. (1950). *American Journal of the Medical Sciences*, **219**, 55.
- Kabat, E. A., Glusman, M., and Knaub, V. (1948). *American Journal of Medicine*, **4**, 653.
- Kabat, E. A., Moore, D. H., and Landow, H. (1942). *Journal of Clinical Investigation*, **21**, 571.
- Kekwick, R. A., and Mackay, M. E. (1954). *Medical Research Council Special Report Series*, No. 286. London: H.M.S.O.
- Kutt, H., McDowell, F., Chapman, L., Pert, J. H., and Hurwitz, L. J. (1960). *Neurology (Minneapolis)*, **10**, 1064.
- Lamoureux, G., and Borda, A. G. (1966). *Clinical and Experimental Immunology*, **1**, 363.
- Laterre, E. C., Heremans, J.-F., and Demanet, G. (1962). *Revue Neurologique*, **107**, 500.
- Lippincott, S. W., Korman, S., Lax, L. C., and Corcoran, C. (1965). *Journal of Nuclear Medicine*, **6**, 632.
- Locoge, M., and Cumings, J. N. (1958). *British Medical Journal*, **1**, 618.
- Lowenthal, A., van Sande, M., and Karcher, D. (1960). *Journal of Neurochemistry*, **6**, 51.
- Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951). *Journal of Biological Chemistry*, **193**, 265.
- Matzke, J., and Clausen, J. (1965). *Acta Neurologica Scandinavica*, **41**, Suppl. No. 13, p. 129.
- Plum, C. M., and Fog, T. (1959). *Acta Psychiatrica et Neurologica Scandinavica*, **34**, Suppl. No. 128.
- Press, E. M. (1956). *Biochemical Journal*, **63**, 367.
- Prineas, J., Teasdale, G., Latner, A. L., and Miller, H. (1966). *British Medical Journal*, **2**, 922.
- Roboz, E., Hess, W. C., and Forster, F. M. (1953). *Neurology (Minneapolis)*, **3**, 410.
- Rowe, D. S., McGregor, I. A., Smith, S. J., Hall, P., and Williams, K. (1968). *Clinical and Experimental Immunology*, **3**, 63.
- Schapira, K., and Park, D. C. (1961). *Journal of Neurology, Neurosurgery and Psychiatry*, **24**, 121.
- Schneck, S. A., and Claman, H. N. (1969). *Archives of Neurology*, **20**, 132.
- Tavolato, B., and De Zanche, L. (1968). *Acta Neurologica Scandinavica*, **44**, 384.
- Tourtellotte, W. W. (1963). *Medical Clinics of North America*, **47**, 1619.
- Tourtellotte, W. W., and Parker, J. A. (1966). *Science*, **154**, 1044.
- Ursing, B. (1965). *Acta Medica Scandinavica*, Suppl. No. 429.
- Volk, B. W., Saifer, A., Rabiner, A. M., and Oreskes, I. (1955). *Archives of Neurology and Psychiatry*, **73**, 66.
- Yahr, M. D., Goldensohn, S. S., and Kabat, E. A. (1954). *Annals of the New York Academy of Sciences*, **58**, 613.
- Ziegler, D. K., and Ross, G. (1955). *Neurology (Minneapolis)*, **5**, 573.